492. Biodistribution and Integration Assessment of AAV1 gag-PR-RT(ΔRNaseH) after Intramuscular Administration in Rabbits

Clade C HIV-1 is responsible for approximately half of all HIV infections worldwide. An initial AAV2 vaccine containing the Clade C HIV-1 genes for the gag, protease and part of the reverse transcriptase proteins (gag-PR-|[Delta]|RT) is currently being tested in clinical trials. A vaccine based on pseudotyped AAV 1 vectors is being developed to be used either on its own on or in combination with other vectors to improve the immune response. Similar to the AAV2-based HIV vaccine, this vaccine also contains the gag, protease and part of the reverse transcriptase proteins (gag-PR-RT|[Delta]|RNaseH) flanked by the AAV2 ITR but is pseudotyped with the AAV1 capsids.